As more psoriasis treatments come to market in both new and existing drug classes, health care payers will need assistance in determining the most cost-effective regimen or sequence of regimens to control budgets. We sought to devise a cost-effectiveness modeling structure that will aid in decision making by highlighting differentiating factors between drugs and meet the changing needs of payers.
